SCHEMBL29454154

SCHEMBL29454154

Cc1cc(N)c(Cl)c(Nc2ccccn2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
MAPK10 P53779 3/20 0.50
GFER P55789 1/20 0.50
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
ALOX12 P18054 1/20 0.40
CCNK O75909 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCND3 P30281 1/20 0.40
CDK9 P50750 1/20 0.40
CDK6 Q00534 1/20 0.40
KDR P35968 2/20 0.40
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP2 O95551 2/20 0.39
CASP6 P55212 2/20 0.39
APAF1 O14727 1/20 0.39
CDC25B P30305 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22232308 1.00 MEN1 (0.50) MEN1KMT2AMAPK10GFERNPC1
SCHEMBL22232146 0.81 PLAU (0.37) MEN1KMT2ANPC1RAB9ATHRB
SCHEMBL29454055 0.81 PLAU (0.37) MEN1KMT2ANPC1RAB9ATHRB
SCHEMBL6836695 0.80 MAPK10 (0.55) MEN1KMT2AMAPK10GFERNPC1
SCHEMBL6832802 0.80 MEN1 (0.55) MEN1KMT2AMAPK10GFERNPC1
SCHEMBL22231909 0.79 LCK (0.38) MEN1KMT2ANPC1RAB9ACCNA2
SCHEMBL29454255 0.79 LCK (0.38) MEN1KMT2ANPC1RAB9ACCNA2
SCHEMBL22232392 0.78 RAB9A (0.43) MEN1KMT2ANPC1RAB9AALOX12
SCHEMBL31723212 0.78 RAB9A (0.43) MEN1KMT2ANPC1RAB9AALOX12
SCHEMBL29454077 0.78 RAB9A (0.43) MEN1KMT2ANPC1RAB9AALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US claimed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US claimed
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US disclosed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP disclosed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS MEN1 1657/4885KMT2A 438/4885MAPK10 4432/4885
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof CBR1, CBR3, HCCS MEN1 3874/4885KMT2A 3264/4885MAPK10 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.